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Cellular senescence is a stress-responsive cell-cycle arrest program that terminates the further 
expansion of (pre-)malignant cells
1,2
. Key signalling components of the senescence machinery, such 
as p16INK4a, p21CIP1 and p53, as well as trimethylation of lysine 9 at histone H3 (H3K9me3), also 
operate as critical regulators of stem-cell functions (which are collectively termed ‘stemness’)3. In 
cancer cells, a gain of stemness may have profound implications for tumour aggressiveness and 
clinical outcome. Here we investigated whether chemotherapy-induced senescence could change 
stem cell- related properties of malignant cells. Gene expression and functional analyses comparing 
2
senescent and non-senescent B-cell lymphomas from Eμ-Myc transgenic mice revealed substantial 
upregulation of an adult tissue stem-cell signature, activated Wnt signalling, and distinct stem-cell 
markers in senescence. Using genetically switchable models of senescence targeting H3K9me3 or 
p53 to mimic spontaneous escape from the arrested condition, we found that cells released from 
senescence re-entered the cell cycle with strongly enhanced and Wnt-dependent clonogenic growth 
potential compared to virtually identical populations that had been equally exposed to  
chemotherapy but had never been senescent. In vivo, these previously senescent cells presented with 
a much higher tumour initiation potential. Notably, the temporary enforcement of senescence in 
p53-regulatable models of acute lymphoblastic leukaemia and acute myeloid leukaemia was found 
to reprogram non-stem bulk leukaemia cells into self-renewing, leukaemia-initiating stem cells. Our 
data, which are further supported by consistent results in human cancer cell lines and primary 
samples of human haematological malignancies, reveal that senescence-associated stemness is an 
unexpected, cell autonomous feature that exerts its detrimental, highly aggressive growth potential 
upon escape from cell-cycle blockade, and is enriched in relapse tumours. These findings have 
profound implications for cancer therapy, and provide new mechanistic insights into the plasticity 
of cancer cells. 
 
Cellular senescence, which is implemented in response to severe cellular insults such as oncogenic 
activation or chemotherapeutic DNA damage, is a failsafe program that protects organismic integrity by 
excluding potentially harmful cells from further expansion
2,4
, and also has a physiological function in 
tissue homeostasis during organ development
1
. Senescence has been shown to cancel the pro-tumorigenic 
potential of Ras-/Raf-driven (pre-)cancerous lesions
5–7
, and to contribute to the outcome of anticancer 
chemotherapy in vivo
8,9
. 
 
Notably, stem-cell functions, collectively referred to as ‘stemness’3, and senescence seem to be co-
regulated by overlapping signalling networks. Key senescence-relevant signalling molecules (for example, 
Bmi-1, p16Ink4a, p21Cip1 or p53) have critical roles in stem-cell maintenance by preventing premature 
exhaustion (reviewed in ref. 3). Senescence-enforcing p53 (also known as Trp53)-, Cdkn2a (also known 
as Ink4a or Arf)- or Suv39h1-encoded gene products raise an initial barrier to the efficient conversion of 
normal cells into induced pluripotent stem cells (see refs 10, 11, and references therein), suggesting an 
underexplored interplay between senescence- and stemness-controlling signalling networks. 
Trimethylation of H3K9, as mediated by the H3K9 methyltransferase Suv39h1 (ref. 12), confers 
senescence by establishing a transcriptionally repressive heterochromatin mark in the vicinity of S-phase-
relevant E2F target genes
6,9,13
, and reflects an epigenetic principle linked to induced pluripotent stem cell 
reprogramming
14
. Using a cancer-unrelated, inducible reprogramming mouse model in which many cells 
primarily senesced, previous studies have shown that factors secreted from these senescent cells facilitated 
the reprogramming of their neighbours
15,16
. Whether the senescence condition promotes cancer stemness, 
especially in a cell-autonomous manner, is not known. Although a permanent senescent cell-cycle block is 
per se incompatible with self-renewal, we report here the senescence-evoked cell-intrinsic reprogramming 
of cancer cells into a stem-like state, and the acquisition of tumour-initiating potential after their forced 
release or spontaneous escape from a chemotherapy-induced senescent cell-cycle arrest.  
3
 As indicated by their strong senescence-associated β –galactosidase (SA-β-gal) activity and other 
previously demonstrated markers of senescence, primary Eμ -Myc transgenic Bcl2-overexpressing 
lymphomas (hereafter referred to as control;Bcl2 lymphomas) serve as a well-established model for 
therapy-induced senescence (TIS)
8,9
. First, we analysed stem-cell-related transcripts in the gene expression 
profiles of 12 matched pairs of primary control;Bcl2 lymphomas that either entered TIS after in vitro 
exposure to the chemotherapeutic agent Adriamycin (ADR) or remained untreated. Using gene set 
enrichment analysis (GSEA), a previously established adult tissue stem-cell (ATSC) signature17 was 
strongly skewed towards the TIS group, but was not found to be enriched in the equally ADR-treated but  
senescence incapable group of Suv39h1-deficient Eμ -Myc;Bcl2 (that is, Suv39h1−;Bcl2)  ymphomas9 
(Fig. 1a and Extended Data Fig. 1a, b). Almost the entire population turned double-positive for the stem-
cell antigen Sca1 and the senescence marker H3K9me3 upon senescence  induction (Fig. 1b, top). 
Furthermore, TIS cells, unlike non-senescent cells, presented with  increased aldehyde dehydrogenase 
(ALDH) and ATP-binding cassette (ABC) transporter activities (Fig. 1b, bottom, and Extended Data Fig. 
1d), both typical properties of stem cells. When assessing human malignancies of various origins, we 
found a notable upregulation of  stem-cell-related transcripts selectively in TIS-capable cell lines as well 
as samples from patients with primary B-cell chronic leukaemia (B-CLL) (Fig. 1c and Extended Data Fig. 
1c, e, f). Moreover, the acquisition of stemness-related properties can also be found in the process of 
oncogene-induced and replicative senescence in cells of various tissue types, including melanocytes, colon 
mucosa and breast epithelial cells (Fig. 1d and Extended Data Fig. 1g). Hence, cancer cells of mouse and 
human origin acquire novel stem-cell features upon entering cellular senescence.  
 
To test whether senescence-associated stemness (SAS) translates into different tumour behaviour upon 
release from the division block, we generated switchable model systems (using 4-hydroxytamoxifen (4-
OHT)-inducible essential senescence mediators Suv39h1 or p53) that can enter full-featured senescence 
with increased levels of stem cell- related transcripts and proteins only when exposed to both 4-OHT and 
ADR (Fig. 2a and Extended Data Fig. 2a–c). After changing to ADR- and 4-OHT-free medium to switch 
Suv39h1 or p53 off again, single-cell analyses revealed that senescent cells resumed sustainable 
proliferation within a few days; that is, they became first double positive for the retained fluorescence-
based senescence marker (a vital stain) and 5-ethynyl-2′ -deoxyuridine (EdU) incorporation, indicating 
restarted DNA synthesis (with the proliferation-repressive H3K9me3 mark gradually vanishing), before 
SA-β -gal activity was eventually lost and S-phase activity fully regained (Fig. 2a and Extended Data Fig. 
2d–g). Therefore senescence is, in principle, a reversible condition, which becomes evident when essential 
senescence maintenance genes are no longer expressed. Importantly, serial replatings in colony formation 
experiments of such previously senescent cells led to significantly more colonies compared to the aliquot 
of never senescent cells of the same lymphoma treated with the same dose of chemotherapy, reflecting the 
now unleashed stemness properties acquired as a latent program during senescence (Fig. 2a, b). The 
enhanced colony-founding potential of previously senescent cells was stable over an extended observation 
period of up to 100 days (reflecting 14 serial replatings; Fig. 2b). Similar results were obtained with p53-
ERTAM as another inducible senescence gatekeeper; with γ -irradiation as an alternative senescence 
trigger; with ADR-exposed human lymphoma cell lines; and with colon cancer cells representing a solid, 
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epithelial cancer type (Extended Data Fig. 3a–f). It is noteworthy that previously senescent cells typically 
retained the ability to re-enter TIS when re-exposed to 4-OHT and ADR, indicating that no selection for 
senescence compromising mutations occurred in previously senescent cells (Extended Data Fig. 3g). 
Previously, an instructive, non-cell-autonomous role has been attributed to the senescence-associated 
secretory phenotype (SASP; reviewed in ref. 2) in models of inducible reprogramming and tissue 
regeneration
15,16
; however, our observations, made in pure, homotypic tumour cell populations, even under 
drastic reduction of SASP factor expression, favour a largely cell-intrinsic mechanism of senescence-
associated reprogramming (Extended Data Fig. 4). Although we cannot completely exclude alternative 
explanations, these and the subsequent data strongly favour senescence-associated stemness as the most 
compelling and consistent interpretation of the observations presented.  
 
Enrichment assays between matched pairs of never senescent versus previously senescent lymphomas 
confirmed the higher growth competitiveness of previously senescent lymphomas both in vitro and in vivo 
(Extended Data Fig. 2h). Importantly, in vivo tumour initiation experiments found previously senescent 
lymphomas produced malignancies at much lower transplanted cell numbers in immune-competent 
recipient mice when compared to never senescent lymphomas (Fig. 2c). Taken together, the SAS program 
exerts its detrimental effect on tumour initiation upon release from TIS, thereby unmasking an unexpected 
tumour-promoting capability of the senescence program.  
 
To test which key stemness pathways drive SAS, we used GSEA in ADR-exposed control;Bcl2 versus 
Suv39h1−;Bcl2 lymphomas for numerous gene sets related to Notch, Hedgehog, and canonical and non-
canonical Wnt signalling. Canonical Wnt and, to some extent, Notch signalling, appeared to be 
significantly enriched in TIS (Extended Data Fig. 5a, b). Because Wnt signalling plays a central role in 
stem-cell renewal in many tissues including the haematopoietic compartment, induces Notch signalling, 
and is required for cancer stem cell development in haematological malignancies
18,19
, we considered 
activation of the Wnt cascade as the putative driver behind the newly acquired stemness features in TIS 
lymphomas. Indeed, we detected enhanced, predominantly nuclear expression and transcriptional 
activation of β-catenin in control;Bcl2 but not in Suv39h1−;Bcl2 lymphomas, as well as in TIS-capable 
human cancer cell lines after ADR treatment (Fig. 3a, Extended Data Fig. 2b and Extended Data Fig. 5c, 
d). Independent of Wnt ligand–receptor stimulation, we identified inhibition of the β-catenin degradation-
promoting glycogen synthase kinase 3β (GSK3β) via activated MEK–MAPK and PI3K–Akt signalling—
which is typically upregulated in senescence20—as the cell-autonomous driver of the Wnt program 
(Extended Data Fig. 6). The implementation of the Wnt program was further promoted by epigenetically 
permissive remodelling at promoters of stem-cell- and Wnt signalling-related genes in previously 
senescent as compared to never senescent cells (Fig. 3b). Accordingly, we found that the increased 
colony-forming potential of previously senescent lymphoma or colon cancer cells was dependent on Wnt 
signalling, as genetic or pharmacological disruption of the Wnt–β-catenin cascade—without preventing 
TIS or profoundly affecting cell viability—neutralized the higher clonogenicity of previously senescent 
cells (Fig. 3c and Extended Data Fig. 7a–d). In contrast to the never senescent cell population, a rarely 
dividing and strongly β-catenin-expressing subpopulation was detectable in the previously senescent cells 
only, and maintained at a stable steady state, explaining the lastingly enhanced colony-forming potential 
5
of previously senescent compared to never senescent cells (Extended Data Fig. 8). Consistently, the 
biology of the previously senescent state translated into shortened survival when previously senescent and 
never senescent cells were propagated in mice, whereas exposure to Wnt inhibitors in vivo or stable 
lymphoma cell transduction with a construct expressing short hairpin RNA (shRNA) against Ctnnb1 
(which encodes β-catenin) improved the poor long-term outcome of mice harbouring previously senescent 
lymphomas (Fig. 3d and Extended Data Fig. 7b, e, f).  
 
Importantly, cell cycle re-entry out of TIS—as a prerequisite to exert stem-cell potential—is not limited to 
conditional, switchable systems, but may, as a rare event, spontaneously occur in control;Bcl2 
lymphomas, as demonstrated by the emergence of EdU-co-positive cells out of a solely SA-β-gal-positive 
senescent cell population (Extended Data Fig. 9). Given their stem-cell potential, we postulated that β–
catenin positive previously senescent cells might be enriched in lymphomas that progressed after 
chemotherapy. Hence, when comparing primary control;Bcl2 lymphomas before therapy with the same 
individual lymphomas that had relapsed after exposure to senescence-inducing cyclophosphamide 
chemotherapy in vivo
8
, we found a much higher fraction of cells positive for nuclear β-catenin in relapse 
lymphomas that also presented with higher expression levels of Wnt target genes (Fig. 3e, f, left). 
Moreover, longitudinally matched biopsy pairs from the same individual patients diagnosed with diffuse 
large B-cell lymphoma (DLBCL) before chemotherapy and at disease recurrence revealed significantly 
more nuclear β-catenin-positive tumour cells in the previously chemotherapy-exposed, re-emerging 
samples (Fig. 3f, right), further supporting a link between activated Wnt signalling in relapsed tumours 
and senescence-related tumour cell reprogramming. Taken together, TIS-associated stemness reflects a 
Wnt-governed capability that is stably maintained in a reprogrammed, hierarchically organized 
subpopulation of post-senescent tumour cells and critically associated with tumour progression and 
treatment failure.  
 
As presumably applying to various human tumours including aggressive lymphomas, Eμ -Myc transgenic 
mouse lymphomas do not originate from a distinct fraction of cancer stem cells, because almost all 
lymphoma cells possess tumour-initiating potential in this model
21
. Consequently, next we asked whether 
cellular senescence might account for the reprogramming of non-stem tumour cells into cancer stem 
cells
22
, in tumour types in which the tumour-initiating capacity is confined to a rare subpopulation. We 
isolated a non-self-renewing population of leukaemia cells from a mouse model of T-cell acute 
lymphoblastic leukaemia (T-ALL) driven by oncogenic KrasG12D and conditional inactivation of p53 via 
a doxycycline-controlled shRNA (shp53)23 (Extended Data Fig. 10a). ADR exposure induced senescence 
in the majority of non-stem leukaemia cells only if p53 expression was not cancelled (Fig. 4a, top). This 
group exhibited a significant conversion to Kit+Sca1+ cells, indicative of putative leukaemia stem cells (P 
= 0.02, compared to ADR-exposed but p53-deficient cells; Fig. 4a, middle), and higher expression of 
stem-cell-related transcripts (Fig. 4a, bottom). Upon release from TIS by knockdown of p53, these 
leukaemia cells resumed proliferation (thereby becoming previously senescent cells), and formed 
significantly more colonies as compared to their equally ADR-treated never senescent leukaemia 
counterparts that remained p53-inactive throughout the experiment (Extended Data Fig. 10b). As reported 
for TIS lymphomas, cells with nuclear β–catenin expression were almost exclusively detectable in the 
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senescent leukaemia cell population, and Wnt inhibitors completely neutralized the increased colony 
formation potential of their previously senescent progeny (Extended Data Fig. 10c, d). Most importantly, 
almost all samples of previously senescent cells—and nearly none of the samples of never senescent 
cells—initiated leukaemias in recipient mice (P = 0.0275, comparing previously senescent and never 
senescent groups); as expected, all Lin− transplants gave rise to leukaemias (P < 0.001, comparing Lin− 
and never senescent groups; Fig. 4b, c). Notably, and further adding to SAS in oncogene-induced 
senescent colon mucosa cells or melanocytes (compare with Fig. 1d), TIS reprogramming is not restricted 
to cells of lymphoid origin, as demonstrated for an acute myeloid leukaemia (AML) mouse model
24
, 
culture established human AML cells, and primary human leukaemic blast samples obtained at diagnosis 
from patients with AML (Extended Data Fig. 10e–l). Thus, cellular senescence is not only associated with 
additional stem-cell features in tumour cells with pre-existing self-renewal capability, but also catalyses 
the cell-autonomous reprogramming of non-stem bulk tumour cells of lymphoid and non-lymphoid origin 
into de novo cancer stem cells.  
 
We present here an unexpected cell-intrinsic link between the senescence program and the acquisition of 
self-renewing properties, which we postulate serves as a physiological rescue mechanism in development 
and tissue homeostasis. We and others have observed that senescence not only occurs in critically stressed 
cells, but also may spread to adjacent cells via SASP components in a paracrine fashion (ref. 25; J.R.D. 
and C.A.S., unpublished observations). We propose that nature equipped normal cells with a latent SAS 
capacity (compare with Extended Data Fig. 1g) to counter the imminent loss of an entire tissue 
compartment due to pro-apoptotic and pro-senescent stresses: in rare cells spontaneously re-entering the 
cell cycle when threatening stresses no longer apply, SAS may become a tissue-replenishing principle. In 
a neoplastic context, cellular senescence—particularly in tumour cells with apoptotic defects—appears to 
be primarily a beneficial response by keeping tumour growth in check. However, post-senescent cells with 
‘hijacked’ SAS exert their detrimental potential at relapse by driving a much more aggressive growth 
phenotype. Therefore, pharmacological strategies to specifically eliminate senescent cells before a fraction 
of them may implement their acquired stemness capacity become, as previously reported by us regarding 
cancer
9
 and by others regarding ageing-related pathologies
26,27
, a critical therapeutic need. 
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MAIN FIGURES: 
 
 
Figure 1 | Therapy-induced senescent cancer cells acquire phenotypic and functional stemness 
features. a, GSEA of an adult tissue stem cell profile
17
 (ATSC; top) in matched pairs of ADR-exposed 
versus untreated control;bcl2 lymphomas (n = 12; left) and Suv39h1
−
;bcl2 lymphomas (n = 5; right). TIS 
lymphomas display more than 80% SA-β-gal-positive blue cells9 (representative photomicrographs from 
four independent experiments). b, Co-expression of the stem cell marker Sca1 and the TIS marker 
H3K9me3 (top) in lymphoma cells as in a, and aldehyde dehydrogenase (ALDH) activity with and 
without the ALDH inhibitor diethylaminobenzaldehyde (bottom) by flow cytometry. Mean percentage of 
positive cells ± s.d.; n = 5 biologically independent samples each. c, Expression of the indicated stem-cell-
related genes in various human cancer cell lines or primary B-CLL samples by quantitative real-time PCR 
(qRT–PCR), related to their ability to enter TIS (ADR-senescent, blue; non-senescent despite ADR 
exposure, white (see Extended Data Fig. 1c for details)). Colours reflect fold induction (between ADR-
treated and untreated samples) from one representative out of three independent experiments (cell lines) or 
four individual samples from patients with B-CLL. Transcripts below the detection level are shown in 
light grey. d, GSEA of the adult tissue stem cell profile in the publicly available transcriptome of 
BRAF
V600E
-infected melanocytes, which senesce in response to Braf activation
7, 28
 (left; seven matched 
pairs), and colon adenomas, which are known to contain a large proportion of senescent cells
29
 (right; five 
APC
Min/+
 mouse adenoma biopsies and six healthy colon tissue samples). 
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Figure 2 | Senescence-released (previously senescent) lymphomas display higher tumour-initiating 
capacity than their never senescent counterparts. a, Growth properties of conditionally senescent 
Suv39h1
−
;bcl2;Suv39h1·ER
T2
 lymphoma cells after five days of ADR ± 4-OHT treatment (Treatment), 
and subsequent passages in 4-OHT/ADR-free medium (Post-treatment, p1–p2; each passage reflecting 
seven days in culture) presented as proliferation (left, mean BrdU/PI-marked S-phase fraction ± s.d., n = 5 
biologically independent samples; BrdU, 5-bromo-2′-deoxyuridine; PI, propidium iodide), SA-β-gal 
staining (middle, mean positive cells ± s.d., n = 5 biologically independent samples), and colony 
formation (right, quantified in b). Flow microscopy images (bottom) of the fluorescent SA-β-gal mark 
together with the proliferation marker EdU (passage 1 shown, see Extended Data Fig. 2g for details) 
demonstrates the outgrowth of senescent (SA-β-gal+) cells. Representative photomicrographs from four 
independent experiments. b, Colony counts of lymphoma cells (treated as in a) in extended serial 
passaging (p1–p14). Graphs show mean colony numbers ± s.d., n = 3 individual lymphomas. Two-tailed 
unpaired t-test with Welch’s correction, comparing ADR- and 4-OHT+ADR pretreated cells at p14. *P < 
0.05. c, Tumour initiation after transplantation of different numbers of Suv39h1
−
;bcl2;Suv39h1·ER
T2
 
lymphoma cells pre-exposed to the indicated treatments in vitro. Bars reflect numbers of lymphoma-
bearing mice out of 10 animals per group transplanted, within an observation period of up to 100 days. P < 
0.001 for comparing never senescent and previously senescent groups (χ2). 
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Figure 3 | Canonical Wnt signalling, activated in TIS, is an essential driver of the enhanced tumour 
initiation capacity exhibited by senescence-released tumour cells. a, Co-expression of the fluorescent 
SA-β-gal marker and β-catenin in ADR-exposed control;bcl2 or TIS-incapable Suv39h1−;bcl2 lymphoma 
cells (left), and corresponding β-catenin transcriptional activities measured as relative TOPflash T-cell 
factor (TCF) reporter signals with FOPflash as a TCF-binding site mutant control (right). Mean percentage 
of double-positive cells or mean relative light units fold change (between ADR-treated and untreated 
samples) ± s.d., respectively (n = 4 biologically independent samples each). The inset shows a 
representative photomicrograph from four independent experiments. b, Colour-coded heat map reflecting 
fold change (between previously senescent and never senescent cells) of permissive H3K4me3 and 
repressive H3K27me3 histone marks at the promoters of indicated ATSC- or Wnt-related (asterisk) genes 
by chromatin immunoprecipitation (n = 3 biologically independent samples). c, Colony formation of never 
senescent versus previously senescent Suv39h1
−
;bcl2;Suv39h1·ER
T2
 lymphomas (passage 2, compare 
with Fig. 2), exposed to the pharmacological Wnt inhibitors (ICG-001, salinomycin) or shRNA against β-
catenin for 7 days. Results reflect mean colony numbers ± s.d. (n = 3 biologically independent samples). 
Two-tailed unpaired t-test with Welch’s correction, *P < 0.05. d, Survival of mice transplanted with 
matched previously senescent or never senescent cells and treated with indicated Wnt inhibitors upon 
palpable lymphoma formation. Cells with shRNA against β-catenin were shRNA-infected before 
transplantation. Boxes frame the 25th to 75th percentile range, with median, minimal and maximal values 
(n = 6 mice per treatment group). Two-tailed, paired t-test, *P < 0.05. e, Expression of Wnt target genes 
(by qRT–PCR) in matched cases of control;bcl2 lymphomas before and after relapse from senescence-
inducing cyclophosphamide treatment in vivo (mean fold change ± s.d., n = 4 biologically independent 
12
samples). f, Nuclear β-catenin expression by immunostaining of lymph nodes from control;bcl2 
lymphoma-bearing mice as in e (left; n = 4 biologically independent samples), and human DLBCL 
biopsies from the same individual patients at diagnosis and at relapse after first-line induction 
chemotherapy (right; n = 5 independent patients). Mean percentage of positive cells ± s.d.; two-tailed, 
paired t-test, *P < 0.05. Representative photomicrographs; scale bar, 100 µm (magnifying inserts 10 µm). 
 
 
 
Figure 4 | Cellular senescence catalyses de novo reprogramming of non-stem bulk leukaemia cells 
into leukaemia-initiating cells. a, Stemness-related features in conditionally senescent mouse 
Kras
G12D
;DOX-shp53-GFP;bcl2 bulk leukaemia cells (lin
−
/Kit
+
/Sca1
+
-depleted) treated for five days with 
ADR ± doxycycline (DOX)). Senescence induction is demonstrated by SA-β-gal staining (top), stem cell 
marker Kit and Sca1 expression analysed by flow cytometry (middle), and relative expression of the 
indicated transcripts by qRT–PCR (bottom). Numbers reflect mean percentages of positive cells (top) or 
average fold induction (middle), ± s.d. (n = 3 biologically independent samples). b, Tumour initiation 
capacity of bulk leukaemia cells pretreated in vitro as in a, cultivated in ADR-free/DOX-supplemented 
medium for an additional two passages and transplanted at indicated cell numbers. Lin
−
 cells were 
propagated without ADR. Numbers indicate leukaemia-bearing mice out of six animals per group 
transplanted, within an observation period of up to 100 days (n = 3 independent primary leukaemia 
samples, each transplanted in two recipient mice). c, Flow cytometry plots showing peripheral blood 
phenotyping of mice transplanted as in b. The GFP
+
 leukaemia cells are depicted in green. The insets 
show photomicrographs of peripheral blood smears stained with haematoxylin and eosin, showing 
leukaemic blasts (typically not detectable in never senescent recipients). One representative out of three 
independent experiments shown. 
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METHODS  
Generation of primary murine lymphomas and leukemias, and utilization of primary human B-cell 
lymphoma, B-CLL and AML samples. All animal protocols used in this study were approved by the 
governmental review board (Landesamt Berlin), and conform to the respective regulatory standards. 
Lymphomas with defined genetic defects were generated by intercrossing Eµ-myc transgenic mice to mice 
carrying loss-of-function alleles at the Suv39h1 locus
30,31
 or to mice harboring a 4-Hydroxytamoxifen (4-
OHT)-inducible p53•ERTAM knock-in allele, encoding a p53-estrogen receptor fusion protein that is 
inactive in the absence of 4-OHT
32
, all in a C57BL/6 background. Eµ-myc transgenic lymphomas that 
formed in Eµ-myc;p53•ERTam/+ mice with an allelic loss of the remaining p53 wild-type allele were 
designated p53•ERTam lymphomas. Suv39h1- lymphomas reflect Eµ-myc lymphomas that arose in 
Suv39h1
-/-
 females, or, due to the X-linkage of the Suv39h1 locus, in Suv39h1
y/-
 males
33
. Genotyping of the 
offspring by allele-specific genomic PCR, monitoring of lymphoma onset and isolation of viable 
lymphoma cells were carried out as described
8,34
. K-Ras-G12D;shp53-GFP-induced T-cell acute 
lymphoblastic leukemias (T-ALL) with tetracycline (i.e. Doxycycline)-dependent shp53 expression 
(“DOX-off”) were generated and isolated following a previously published protocol with minor 
modifications
23,35
. The N-Ras-G12D/MLL-AF9-driven mouse model of acute myeloid leukemia (AML), 
co-expressing a reverse tetracycline transactivator (“Tet-on competent”), was generated as previously 
published
24
. 6–8-week-old C57BL/6 (“wild type”) female mice were used as recipients for in vivo 
lymphoma or leukemia propagation. No randomization or blinding was used to allocate experimental 
groups.  
The use of tumor biopsies (i.e. bone marrow aspirates, lymph-node biopsies, or peripheral blood samples 
obtained for the initial diagnosis or follow-up analyses of B-cell leukemia [B-CLL], diffuse large B-cell 
lymphoma [DLBCL] or acute myeloid leukemia [AML] patients) as anonymous samples after informed 
patient consent was approved by the local ethics commission of the Charité - Universitätsmedizin Berlin 
(reference EA4/085/07 and EA4/061/11).  
Cell culture, plasmids and retroviral gene transfer. Isolated mouse lymphoma cells and primary human 
AML samples (tumor cell-purified by Ficoll density-gradient centrifugation and red cell lysis) were short-
term cultured in standard medium on irradiated NIH3T3 fibroblast feeders
36
. Primary human B-cell 
malignancies were cultivated in a “CD40 system”37, i.e. in the same medium further supplemented with 
100 IU/ml of recombinant human interleukin-4 (Peprotech) on irradiated NIH3T3 cells stably expressing 
the human CD40 ligand. Human cancer cell lines were obtained from DSMZ (Leibniz-Institut Deutsche 
Sammlung von Mikroorganismen und Zellkulturen GmbH), ATCC or Biomol: RCK8 (DSMZ-No. ACC-
561), Eheb (DSMZ-No. ACC-67), K562 (DSMZ-No. ACC-10), Mec1 (DSMZ-No. ACC-497), Molm13 
(DSMZ-No. ACC-554), SW480 (DSMZ-No. ACC-313), LS174T (DSMZ-No. ACC-759), DLD-1 
(DSMZ-No. ACC-278), Caco-2 (DSMZ-No. ACC-169), SKMel28 (ATCC No. HTB-72), MeWo (ATCC 
No. HTB-65), WM266.4 (Biomol No. WM266-4-01). Omm2.3 cells were kindly provided by Martina J. 
Jager. The cells were cultivated according to supplier’s recommendations and regularly tested for 
mycoplasma contamination. The cell lines bought within last 4 years were not additionally authenticated 
14
(RCK8, Eheb, Mec-1). All other cell lines were authenticated by DSMZ using SNP-based multiplex 
approach in October 2017. SNP profiles matched known profiles or were unique (Omm2.3). Retroviral 
supernatants, generated by transient transfection of Phoenix-Eco packaging cells with murine stem cell 
retrovirus (MSCV)-based constructs, were used to stably infect Eµ-myc transgenic lymphomas, K-Ras-
G12D;shp53-GFP T-ALL cells, N-Ras-G12D/MLL-AF9 AML cells or human cancer cell lines 
(engineered to express the ecotropic virus receptor as described
38
). Freshly isolated cells were first 
infected with an MSCV retrovirus encoding murine or human Bcl2 and a blasticidin antibiotic resistance 
gene. Bcl2-overexpressing Eµ-myc;Suv39h1
-
 lymphoma were subsequently infected with Suv39h1•ERT2 
cDNA, encoding murine full-length Suv39h1, fused in frame with the coding sequence of an 4-OHT-
inducible estrogen receptor mutant (ER
T2
; see [
39
]), subcloned into MSCV-IRES-GFP or MSCV-IRES-
DsRed vectors. GFP- or DsRed-positive cells were purified in a fluorescence-activated cell sorter (FACS 
Aria II, BD Biosciences, FACS core unit of BCRT, Berlin). TOPflash and FOPflash reporter constructs 
(reflecting the wild-type or mutant TCF-binding promoter region followed by a Firefly luciferase-
encoding cDNA) were subcloned from the original pGL3 vector into a self-inactivating MSCVSIN-DsRed 
plasmid, stably transferred into mouse lymphoma cells or human cell lines (expressing the ecotropic virus 
receptor), and flow-sorted for DsRed-positive cells. NF-κB inactivation was achieved by stable 
overexpression of an IκBαΔN construct (NF-κB super-repressor [NF-κB-SR]) in control;bcl2 cells as 
reported before
40
. Wnt pathway activation was achieved by transducing ctrl;bcl2 lymphomas with a 
stabilized murine β-catenin (encompassing an N-terminal 90-amino acid deletion, ΔNβ-catenin)-encoding 
MSCV-IRES-GFP retrovirus. To stably knock-down β-catenin expression, a previously published shRNA 
sequence
41
 was subcloned into the pSuperRetro plasmid to infect Suv39h1
-;bcl2;Suv39h1•ERT2 cells. An 
MSCVSIN-based construct containing a miR30-shRNA against murine p53 under a tetracycline-dependent 
promoter
42
 was used to transfect N-Ras-G12D/MLL-AF9;bcl2 cells. Stable TP53 knock-down in human 
cell lines RCK8, Molm-13 and LT174T was achieved by lentiviral transduction with a previously 
published shp53 construct
43
 in the pLKO.1-puro vector (Addgene plasmid number 19119). 
In vitro- and in vivo-treatments. For induction of cellular senescence in vitro, Adriamycin (ADR; 
Sigma), a topoisomerase II inhibitor widely used in the clinic to treat lymphomas and other malignancies, 
was added once at a concentration of 0.05 µg/ml in all experiments, except for Eheb, Mec1, Molm13 and 
RCK8 cell lines, which were treated with 0.01 µg/ml ADR, and the K562 cell line that received 
0.025 µg/ml ADR. For conditional activation of ER
Tam
- or ER
T2
-fused constructs, the cells were 
additionally exposed over five days to 1 µM of 4-OHT (Sigma) or the equivalent volume of the ethanol-
based solvent. Cellular senescence was assessed after five days of treatment. Pharmacological inhibition 
of the Wnt pathway or kinases involved in modulating Wnt signaling was performed by adding small 
molecule inhibitors to cells for the last 48 hours of the senescence-inducing ADR ± 4-OHT treatment: 
Wnt inhibitors ICG-001 (10 µM; Enzo Life Sciences) and Salinomycin (1 µM; Sigma), MAPK inhibitor 
PD325901 (10 nM; Selleckchem), MEK inhibitor PD98059 (25 µM; Selleckchem), PI3K inhibitor 
LY294002 (10 µM, Sigma-Aldrich), Akt inhibitor MK-2206 (200 nM, Selleckchem) or GSK3β inhibitor 
CHIR99021 (1 µM; Sigma-Aldrich). For Wnt-modulating treatments upon senescence-release, passage-2 
NS and PS cells were used (i.e. ADR ± 4-OHT-pretreated Eµ-myc;Suv39h1
-;bcl2;Suv39h1•ERT2 cells, 
further propagated in 4-OHT/ADR-free medium for 14 days). Matched pairs of PS and NS cells were 
15
exposed to Wnt inhibitors as described above or to recombinant mouse Wnt3a (10 ng/ml, R&D Systems), 
recombinant mouse R-Spondin 2 (Rspo2; 20 ng/ml, R&D Systems), combination of the two ligands (same 
concentration as for single treatments) or to the GSK3β inhibitor CHIR99021 (1 µM, Sigma-Aldrich) for 
48 hours regarding the gene expression analysis or for seven days (in methylcellulose medium) regarding 
colony formation assessment. The Doxycycline (DOX)-dependent repression of an shRNA against p53 in 
murine K-Ras-G12D;shp53-GFP T-ALL samples (DOX-off) or shRNA activation in murine N-Ras-
G12D/MLL-AF9 AML samples (DOX-on) was achieved by supplementing the culture medium with 
1 µg/ml of Doxycycline (Sigma). 
For in vivo-experiments, 1 x 10
6
 Eµ-myc;Suv39h1
-;bcl2;Suv39h1•ERT2 lymphoma or 5 x 106 K-Ras-
G12D;shp53-GFP T-ALL leukemia cells (or 1 x 10
6
 lineage
-
 [lin
-
] cells as a positive control), if not 
otherwise indicated, were transplanted by tail vein injection into immunocompetent recipient mice. In case 
of K-Ras-G12D;shp53-GFP T-ALL leukemia samples, recipient mice were irradiated with 6 Gy 24 hours 
prior to transplantation. Lymphoma formation was diagnosed when palpable lymph-node enlargements 
had formed. Tumor size of 16 mm (corresponding to approximatelly 4 lymph nodes of 4 mm in diameter) 
was approved by Landesamt Berlin as experiment end-point criteria. This limit was not exceeded in any of 
the performed experiments. Leukemia manifestation was diagnosed by flow cytometry-based detection of 
GFP-positive cells in the peripheral blood at the time mice presented with general signs of pre-terminal 
sickness (> 20% weight loss or other symptoms of severe sickness). If no signs of sickness were noted, the 
experiments were ended by 70% tumor burden in peripheral blood. ICG-001 and salinomycin were 
applied i.p. daily (both at a dose of 10 mg/kg body weight), starting from palpable lymphoma formation 
until a pre-terminal disease stage was reached. Time-to-death was defined as the latency between 
transplantation and a pre-terminal disease stage. Upon CO2 euthanasia, single-cell suspensions were 
isolated from enlarged organs as described before
8,36
.  
Analysis of growth parameters, viability, stem cell and senescence markers. Cell-cycle analysis by 5-
bromo-2-deoxyuridine/propidium iodide (BrdU/PI)-based flow cytometric measurement was performed as 
described before
33
. Cytospin preparations of suspension cultures for subsequent SA-β-gal analyses or 
immunostainings were carried out as previously described
6,44,45
. Carboxyfluorescein succinimidyl ester 
(CFSE) labeling was performed on day 3 after starting ADR ± 4-OHT treatment, using the CellTrace™ 
Far Red Cell Proliferation Kit for flow cytometry (Molecular Probes, cat. no. C34564) according to 
manufacturer’s recommendations. CFSEhigh cells were sorted on treatment day 5 on an S3e™ Cell Sorter 
(Bio-Rad). For β-catenin co-staining, CFSE-labeled cells were fixed in 4% paraformaldehyde, 
permeabilized by Saponin in 1% BSA (LifeTechnologies, cat. no. 10635), stained with Alexa Fluor
®
 488 
mouse anti-β-catenin antibody according to manufacturer’s recommendations (BD Pharmingen, cat. no. 
562505), and acquired on an ImageStream
®
X Mark II Imaging Flow Cytometer (Amnis, MerckMillipore). 
EdU labeling was performed on treatment day 5 by the Click-iT
®
 EdU Pacific Blue™ Flow Cytometry 
Assay Kit according to manufacturer’s recommendations (Molecular Probes, cat. no. C10418). For the 
fluorescent SA-β-gal labeling, cells were incubated in 75 µM chloroquine solution for 1 hour followed by 
exposure to the C12FDG substrate (5-Dodecanoyilaminofluorescein-di-β-D-galactopyranoside; ImaGene 
Green™ C12FDG lacZ Gene Expression Kit, Molecular Probes, cat. no. I2904) for 20 minutes at 37°C in 
PBS (pH 5.5, with 1 mM MgCl2) and analyzed on ImageStream
®
X Mark II Imaging Flow Cytometer. 
16
Cell viability was evaluated by Annexin V (BD Pharmingen, cat. no. 556419) and PI (5 µg/ml, Sigma-
Aldrich) staining, analyzed in a FACSCalibur flow cytometer (BD Biosciences). Viable cells were 
detected as Annexin V/PI-double-negative. ABC transporter activity was analyzed using the eFluxx-
ID
®
 Gold multidrug resistance kit (Enzo Life Sciences), and aldehyde dehydrogenase (ALDH) activity 
using the ALDEFLUOR™ kit (Stemcell Technologies)46, according to the manufacturer’s instructions. 
Colony-forming unit (CFU) assays were performed by plating 10
2
 or 10
3
 cells in 1 ml of methylcellulose 
medium (MethoCult M3134 for mouse cells, or H4100 for human cells, Stem Cell Technologies). For 
mouse cells, the medium was supplemented with recombinant murine interleukin (IL)-3 (1 ng/ml, 
Miltenyi), recombinant murine IL-6 (10 ng/ml, Miltenyi), recombinant murine IL-7 (0.1 ng/ml, 
Peprotech), and recombinant murine stem cell factor (SCF, 50 ng/ml, Peprotech). For indicated assays, the 
medium was further supplemented with ADR (0.05 µg/ml), 4-OHT (1 µM), DOX (1 µg/ml), ICG-001 
(10 µM), salinomycin (1 µM)
47,48
. Wnt3a (10 ng/ml), Rspo2 (20 ng/ml) or GSK3β inhibitor CHIR99021 
(1 µM). Clusters of > 50 cells were scored as colonies, using bright-field or fluorescent microscopy. For 
serial passaging, cells were washed out of methylcellulose with warm PBS after seven days (mouse B-cell 
lymphoma cells) or ten days (mouse T-ALL cells), counted and plated in fresh methylcellulose medium 
(1,000 cells/ml). Regarding luciferase-based Wnt reporter assays, cells stably transfected with TOPflash-
MSCVSIN or FOPflash-MSCVSIN were ADR-exposed in a senescence-inducing schedule as described 
above. The luminescence signals were measured with the ONE-Glo™ kit (Promega) according to 
manufacturer’s instructions and normalized to viable cell counts. For depletion of lin- cells from K-Ras-
G12D;shp53-GFP T-ALL samples or N-Ras-G12D/MLL-AF9 AML samples, cells were labeled with a 
cocktail of biotinylated lineage marker antibodies (BD Biosciences, cat. no. 559971) followed by 
Streptavidin-PE (BD Biosciences, cat. no. 554061). GFP
+
/PE
+
 cells were flow-sorted in a FACS Aria II 
(BD Biosciences). For depletion of CD34
+
 cells from Bcl2-transfected Molm-13 cell line, cells were 
stained with a directly conjugated anti-CD34-APC antibody (1:200, BD Biosciences, cat. no. 560940), and 
CD34
- 
cells were sorted in a FACS Aria II (BD Biosciences). 
RNA-based expression analysis. For microarray-based gene expression profiling of untreated or 5 day-
ADR-exposed control;bcl2 or Suv39h1
-
;bcl2 lymphomas, RNA was isolated and processed as previously 
reported
40
.   
The list of 5,401 probe sets differentially expressed between untreated and ADR-treated control;bcl2 
lymphomas was determined by analysis of variance (ANOVA, cut-off at q < 0.05). The list of filtered 
genes was ranked according to expression fold-changes, and the genes belonging to the ATSC
17
 or core 
ESC signature
49
 were marked in orange and blue, respectively.  
Gene Set Enrichment Analysis (GSEA) was performed with the GSEA v2.0 software (Broad Institute 
of the MIT [Massachusetts Institute of Technology] and Harvard, http://www.broad.mit.edu/gsea)
50
 on 
transcriptome data produced in our laboratory (GSE31099 and GSE44355) or on publicly available 
transcriptome data sets downloaded from the Gene Expression Omnibus (GEO; 
https://www.ncbi.nlm.nih.gov/geo/): normal colon epithelium and colon adenomas from APC
Min/+
 mice 
(GSE422, samples GSM6191-GSM6201), Braf-V600E-infected human melanocytes (GSE46801), human 
mammary epithelial cells in p16
INK4a
-dependent stasis or telomere shortening-induced agonescence 
17
(GSE16058), normal human foreskin BJ fibroblasts in replicative senescence (GSE13330, samples 
GSM336385-GSM336628) and normal human mesenchymal stem cells in replicative senescence 
(GSE9593, samples GSM242185, GSM242668-9 and GSM242672-4). Probed gene sets were taken 
without further change from the indicated publications, downloaded from the Molecular Signature 
Database (MsigDB) of the Broad Institute (http://software.broadinstitute.org/gsea/msigdb/collections.jsp) 
or from the Gene Ontology (GO) browser AmiGO (“GO Cell cycle process” [GO:0022402], GO “Wnt 
signaling pathway” [GO0016055], GO “Canonical Wnt receptor signaling” [GO:0060070], GO 
“Noncanonical Wnt signaling” [GO0035567], GO “Notch signaling pathway” [GO0007219], GO 
“Smoothened signaling pathway” [GO0007224]), or generated from the gene list reflecting the Mouse 
Wnt Signaling Pathway PCR Array (SA Biosciences; genes from this list annotated to have a role in cell 
growth and proliferation were used as a separate gene set, 
http://www.sabiosciences.com/rt_pcr_product/HTML/PAMM-043A.html#function). Normalized 
enrichment scores (NES) with P values < 0.05 and false discovery rate (FDR) < 0.25 were considered 
statistically significant.  
For quantitative reverse-transcriptase PCR (qRT-PCR) analyses of stem cell-related genes in 
lymphoma cells, RNA extracted with Trizol (Invitrogen) was transcribed into cDNA using SuperScript™ 
II reverse transcriptase (Invitrogen). A panel of established stem cell-related markers consisting of murine 
Abcg2, Cebpb, c-kit, Cd34, Cd44, Cd133, Cd150, Klf4, Sca1 or human ABCG2, CD34, CD44, CD133, 
CD150, LGR5, a panel of Wnt signaling targets: Ccnd1, Fosl1, Fzd3, Id2, Met, as well as a panel of 
established murine SASP factors: Igfbp6, Ccl2, Ccl20, Cxcl1, Ctgf, Il6, Kitl and Tnfa were analyzed by 
qRT-PCR using commercially available Taqman assays (Applied Biosystems). Transcript quantification 
was calculated as 2
(-ΔCt)
 based on ΔCt = ΔCttreated - ΔCtuntreated, with GAPDH transcript levels as an 
internal control.  
Protein-based expression analyses. Immunophenotyping by flow cytometry was carried out as 
described
8,45
, using the primary antibodies directed against human CD34 (BD Biosciences, cat. 
no. 560940, 1:200), or against mouse antigens: H3K9me3 (Abcam, ab8898, 1:2000), β-catenin (BD 
Biosciences, cat. no. 50-2567, 1:20), Thy1.2 (BD Biosciences, cat. no. 553005, 1:200), c-Kit (BD 
Biosciences, cat. no. 553355, 1:200), Sca1 (BD Biosciences, cat. no. 557404, 1:200), followed by 
secondary antibodies: anti-rabbit AlexaFluor
®
 594 (Invitrogen A21207, 1:200) and Streptavidin-APC (BD 
Biosciences, cat. no. 554067, 1:2000).  
For immunoblotting analyses whole-cell pellets were lysed in Laemmli sample buffer (60 mM Tris-
HCl at pH 6.8, 10% glycerol, 2% SDS, 5% 2-mercaptoethanol) supplemented with protease and 
phosphatase inhibitors, resolved by electrophoresis on a 12% SDS polyacrylamide gel (SDS-PAGE), 
transferred onto an Immobilon-P membrane (Millipore) and probed using antibodies against total β-
catenin (BD Biosciences, cat. no. 610153, 1:200), active β-catenin (dephosphorylated at serine 37 [Ser37] 
and threonine 41 [Thr41]; Millipore, cat. no. 05-665, 1:1000), H3K9me3 (Abcam, ab8898, 1:2,000), total 
Erk (Cell Signaling Technology [CST], cat. no. 9102, 1:1000), phospho-Erk1/2 (i.e. Erk1/2-P-
Thr202/Tyr204; CST, cat. no. 4376, 1:1000), total Akt (CST, cat. no. 9272, 1:1000), phospho-Akt (i.e. 
Akt-P-Ser473; CST, cat. no. 4060, 1:2000), total GSK3β (CST, cat. no. 12456, 1:1000), phospho-GSK3β 
18
(i.e. GSK3β-P-Ser9; CST, cat. no. 5558, 1:1000) and α-Tubulin (Sigma, T5168, 1:500) as a loading 
control.  
For immunofluorescence, cells were fixed in 4% paraformaldehyde, permeabilized with 0.1% TritonX-
100/PBS, blocked in 1% bovine serum albumin supplemented with the anti-mouse Cd32/Cd16 antibody 
(BD Biosciences, cat. no. 53142, 1:50) and incubated with a primary antibody against total β-catenin 
(1:200), followed by 0.01% Tween 20 as detergent buffer and AlexaFluor
®
 594 (Invitrogen A11008, 
1:5,000) as a secondary anti-mouse IgG antibody. The slides were stained with 4,6-diamidino-2-
phenylindole (DAPI, Biolegend, cat. no. 422801, 1:1,000 in PBS) as a nuclear counterstain, and mounted 
with Mowiol 4-88 (Calbiochem). Immunohistochemistry was performed on formalin-fixed, paraffin-
embedded lymph-node sections as described
33
. Cryo-sections of murine lymph-nodes were stained with an 
FITC-conjugated antibody against total β-catenin (BD Biosciences, cat. no. 562505, 1:200), and human 
DLBCL sections were stained with a primary antibody against total β-catenin (BD Biosciences, cat. no. 
610153, 1:200), followed by a secondary anti-mouse IgG antibody (1:1000, Dako REAL™ Detection 
System [labeled streptavidin-biotin], Dako, cat. no. K5005). 
Global proteome analysis. Suv39h1
-;bcl2;Suv39h1•ERT2 cells were sampled in ice-cold methanol after 
five days of ADR ± 4-OHT treatment. 50 µg of the protein extracts were digested using an xt-PAL (CTC 
Analytics) pipetting robot with the Chronos software package (Axel Semrau), reduced with 1 mM tris(2-
carboxyethyl) phosphine (TCEP). Free sulfhydryl groups were carbamidomethylated using 5.5 mM 
choloroacetamide. The proteins were digested using 0.5 µg sequencing-grade endopeptidase LysC (Wako) 
for 3 hours at room temperature, and subsequently diluted with four volumes of 50 mM ammonium 
bicarbonate. Tryptic digestion occurred during 10 hours at room temperature using 1 µg of sequencing-
grade trypsin (Promega). The reaction was stopped by adding trifluoroacetic acid (TFA) to a final pH of 2. 
The peptides were purified by using C18-stage tips (3M)
51
. By applying the dimethyl labeling technique, 
the untreated lymphoma samples, serving as the reference, were “light”-labeled, while others (ADR ± 4-
OHT-treated) were “heavy”-labeled,  on the xt-PAL machine by automatically adding 4 µl light (+28 Da) 
or heavy formaldehyde (+32 Da) and 4 µl cyanoborohydride to a final concentration of 0.8%
52
. The 
reaction was carried out overnight, quenched by 16 µl of 50 mM Ammoniumbicarbonate buffer and 
acidified by 8 µl 50% TFA. The “heavy”- and “light”-labeled samples were mixed at a 1:1 ratio and 
measured as technical duplicates on a Q-Exactive mass spectrometer (Thermo-Fisher) coupled to a 
Proxeon nano-LC system (Thermo-Fisher) in data-dependent acquisition mode, selecting the top-10 peaks 
for higher-energy collisional dissociation fragmentation. A three-hour gradient (solvent A: 5% 
acetonitrile, 0.1% formic acid; solvent B: 80% acetonitrile, 0.1% formic acid) was applied to the samples 
using a custom-made nano-LC column (0.075 mm x 250 mm, 3 µm Reprosil C18, Dr. Maisch GmbH). 
The peptides were eluted in gradients of 4 to 76% acetonitrile and 0.1% formic acid in water at flow rates 
of 0.25 μl/min. Mass spectrometric (MS) acquisition was performed at a resolution of 70,000 in the scan 
range from 300 to 1,700 m/z. Dynamic exclusion was set to 30 s and the normalized collision energy to 
26eV. For the automatic interpretation of the recorded spectral data, the MaxQuant software version 
1.2.2.5 (Max Planck Institute) was employed, using a multiplicity of 2 for dimethyl labeling
53
. An FDR of 
0.01 was applied on peptide and protein level, and an Andromeda-based search was performed using a 
mouse International Protein Index database (ipi.MOUSE.v3.84.fasta). MS measurement data were log-
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transformed regarding the heavy/light ratios using the R-statistical software (R Foundation for Statistical 
Computing, Vienna, Austria). Three replicates were used to calculate mean values and significance levels 
using the Wilcoxon test. All identifications with a -log10-transformed P value > 1 were considered 
significant.  
Chromatin immunoprecipitation. Chromatin immunoprecipitation was performed according to Young 
and colleagues
54
 with minor modifications. 1 x 10
7
 cells were fixed for 20 minutes in a 1% formaldehyde 
solution. The fixation was stopped with 0.1 M glycine, the cell pellet was lysed and sonicated in 300 µl 
buffer LB3
54
 (Bioruptor
®
 Sonicator, two cycles of 15 minutes each at high power in pulsed mode 
[30 seconds on, 30 seconds off]). 30 µl of 10% Triton X-100 was added and the sample was centrifuged at 
13,000 rpm for 10 min at 4°C. The supernatant was removed and an aliquot was saved as input DNA 
sample. For immunoprecipitation, 140 µl of the supernatant was mixed with 50 µl of Dynabeads
®
 
Protein G (Life Technologies/Invitrogen), pre-coated with 5 µg of an H3K4me3 antibody (A5051-001P, 
Diagenode) or an H3K27me3 antibody (#39155, Active Motif) and incubated at 4°C overnight. After 
incubation, the beads were magnetically separated from the supernatant, washed and eluted. Following 
reverse-crosslinking, RNaseA and Proteinase K digestion
54
, the DNA was phenol/chloroform-extracted, 
and used as a template for quantitative PCR. Sequence information of the specific primers used is available 
upon request. Enrichments were calculated according to the ΔΔCt method, with Prame as endogenous 
control, and the input as calibrator. The values of the relative enrichments for the 4-OHT/ADR-treated 
samples were divided by the corresponding ADR sample values. 
Statistical evaluation. Based on previous experience with the Eµ-myc transgenic mouse lymphoma 
model, sample sizes typically reflect three to five individual primary tumors as independent biological 
replicates. For assessing long-term outcome after in vivo-treatments, six or more tumor-bearing animals 
per arm were used. No statistical method was used to predetermine sample size. No data were excluded, 
all probes/animals that met proper experimental conditions were included in the analysis. For purposes of 
tumor-initiation assays, a transplanted mouse scored positive if a palpable lymphadenopathy developed at 
any time-point during the observation period of 100 days. The survival data were analyzed using the 
ELDA (Extreme Limiting Dilution Analysis) software package at 
http://bioinf.wehi.edu.au/software/elda/
55
 with confidence interval of 95%. All quantifications from 
staining reactions (e.g. immunostainings or SA-β-gal assays) reflect at least three samples with at least 
100 events counted (typically in three different areas) each. If not stated otherwise, data are presented as 
arithmetic means ± standard deviation (s.d.) and statistical analyses were based on paired or unpaired two-
sided t-tests. The data not following normal distribution (by Kolmogorov-Smirnov test) was analyzed by 
unpaired t-test with Welch’s correction. Similar variance between groups was not assumed. The whisker 
plot boxes indicate the first and third quartiles, and the upper and lower bars minimum and maximum 
values within 1.5 × interquartile range. For GSEA, the non-parametric Kolmogorov-Smirnov test was 
applied. Unless stated otherwise, a P value < 0.05 was considered statistically significant. 
Data availability. Microarray data sets were deposited at the Gene Expression Omnibus repository (GEO) 
of the National Center for Biotechnology Information (at 
http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?token=nxijbauwaomekhw&acc=GSE31099 and 
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http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE44355) under the accession numbers GSE31099 
and GSE44355 (for control;bcl2 and Suv39h1
-
;bcl2 lymphomas, respectively). All other datasets generated 
during this study are available from the corresponding author on reasonable request. 
 
Supplementary references: 
 
30. Adams, J. M. et al. The c-myc oncogene driven by immunoglobulin enhancers induces lymphoid malignancy in 
transgenic mice. Nature 318, 533-538 (1985). 
31. Peters, A. H. et al. Loss of the Suv39h histone methyltransferases impairs mammalian heterochromatin and 
genome stability. Cell 107, 323-337 (2001). 
32. Martins, C. P., Brown-Swigart, L. & Evan, G. I. Modeling the therapeutic efficacy of p53 restoration in tumors. 
Cell 127, 1323-1334 (2006). 
33. Reimann, M. et al. Tumor stroma-derived TGF-ß limits Myc-driven lymphomagenesis via Suv39h1-dependent 
senescence. Cancer Cell 17, 262-272 (2010). 
34. Schmitt, C. A. et al. Dissecting p53 tumor suppressor functions in vivo. Cancer Cell 1, 289-298. (2002). 
35. Premsrirut, P. K. et al. A rapid and scalable system for studying gene function in mice using conditional RNA 
interference. Cell 145, 145-158 (2011). 
36. Schmitt, C. A., McCurrach, M. E., de Stanchina, E., Wallace-Brodeur, R. R. & Lowe, S. W. INK4a/ARF 
mutations accelerate lymphomagenesis and promote chemoresistance by disabling p53. Genes Dev. 13, 2670-
2677 (1999). 
37. Banchereau, J., de Paoli, P., Valle, A., Garcia, E. & Rousset, F. Long-term human B cell lines dependent on 
interleukin-4 and antibody to CD40. Science 251, 70-72 (1991). 
38. Schmitt, C. A., Rosenthal, C. T. & Lowe, S. W. Genetic analysis of chemoresistance in primary murine 
lymphomas. Nat. Med. 6, 1029-1035. (2000). 
39. Feil, R., Wagner, J., Metzger, D. & Chambon, P. Regulation of Cre recombinase activity by mutated estrogen 
receptor ligand-binding domains. Biochem. Biophys. Res. Commun. 237, 752-757 (1997). 
40. Jing, H. et al. Opposing roles of NF-kB in anti-cancer treatment outcome unveiled by cross-species 
investigations. Genes Dev. 25, 2137-2146  (2011). 
41. Yang, D. H. et al. Wnt5a is required for endothelial differentiation of embryonic stem cells and vascularization 
via pathways involving both Wnt/beta-catenin and protein kinase Calpha. Circ. Res. 104, 372-379 (2009). 
42. Dickins, R. A. et al. Probing tumor phenotypes using stable and regulated synthetic microRNA precursors. Nat. 
Genet. 37, 1289-1295 (2005). 
43. Godar, S. et al. Growth-inhibitory and tumor- suppressive functions of p53 depend on its repression of CD44 
expression. Cell 134, 62-73 (2008). 
44. Dimri, G. P. et al. A biomarker that identifies senescent human cells in culture and in aging skin in vivo. Proc. 
Natl. Acad. Sci. U. S. A. 92, 9363-9367 (1995). 
45. Reimann, M. et al. The Myc-evoked DNA damage response accounts for treatment resistance in primary 
lymphomas in vivo. Blood 110, 2996-3004 (2007). 
46. Greve, B., Kelsch, R., Spaniol, K., Eich, H. T. & Gotte, M. Flow cytometry in cancer stem cell analysis and 
separation. Cytometry A. 81, 284-293 (2012). 
21
47. Gupta, P. B. et al. Identification of selective inhibitors of cancer stem cells by high-throughput screening. Cell 
138, 645-659 (2009). 
48. Lu, D. et al. Salinomycin inhibits Wnt signaling and selectively induces apoptosis in chronic lymphocytic 
leukemia cells. Proc. Natl. Acad. Sci. U. S. A. 108, 13253-13257 (2011). 
49. Kim, J. et al. A Myc network accounts for similarities between embryonic stem and cancer cell transcription 
programs. Cell 143, 313-324 (2010). 
50. Subramanian, A. et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-
wide expression profiles. Proc. Natl. Acad. Sci. U. S. A. 102, 15545-15550 (2005). 
51. Rappsilber, J., Mann, M. & Ishihama, Y. Protocol for micro-purification, enrichment, pre-fractionation and 
storage of peptides for proteomics using StageTips. Nat. Protoc. 2, 1896-1906 (2007). 
52. Boersema, P. J., Raijmakers, R., Lemeer, S., Mohammed, S. & Heck, A. J. Multiplex peptide stable isotope 
dimethyl labeling for quantitative proteomics. Nat. Protoc. 4, 484-494 (2009). 
53. Cox, J. & Mann, M. MaxQuant enables high peptide identification rates, individualized p.p.b.-range mass 
accuracies and proteome-wide protein quantification. Nat. Biotechnol. 26, 1367-1372 (2008). 
54. Lee, T. I., Johnstone, S. E. & Young, R. A. Chromatin immunoprecipitation and microarray-based analysis of 
protein location. Nat. Protoc. 1, 729-748 (2006). 
55. Hu, Y. & Smyth, G. K. ELDA: extreme limiting dilution analysis for comparing depleted and enriched 
populations in stem cell and other assays. J. Immunol. Methods 347, 70-78 (2009). 
56. Ivanova, N. B. et al. A stem cell molecular signature. Science 298, 601-604 (2002). 
57. Coppe, J. P., Desprez, P. Y., Krtolica, A. & Campisi, J. The senescence-associated secretory phenotype: the 
dark side of tumor suppression. Annu. Rev. Pathol. 5, 99-118 (2010). 
58.  Whitfield, M. L. et al. Identification of genes periodically expressed in the human  
       cell cycle and their expression in tumors. Mol. Biol. Cell 13, 1977-2000 (2002). 
59.  Hu, Z. et al. The molecular portraits of breast tumors are conserved across microarray platforms. BMC 
Genomics 7, 96 (2006). 
60.  Chambers, S. M. et al. Hematopoietic fingerprints: an expression database of stem cells and their progeny. Cell 
Stem Cell 1, 578-591 (2007). 
 
 
  
22
EXTENDED DATA  
 
Extended Data Figure 1 | Senescent cells of mouse and human origin present with enhanced 
stem cell markers and functionalities. a, 5,401 probe sets (corresponding to 3,867 genes) 
differentially expressed in TIS were determined from the transcriptome data comparing untreated 
and ADR-senescent primary control;bcl2 lymphomas by two-way ANOVA adjusted for multiple 
testing (cut-off q < 0.05, n = 12 biologically independent samples). 181 out of 737 genes 
belonging to an ATSC
17
 or 43 out of 337 genes of core embryonic stem cell (ESC) signature
49
 
were detected and marked orange and blue, respectively, in the fold-change-ranked gene list. 
Whereas the expression of core ESC genes was not correlated with senescence, ATSC transcripts 
exhibit a strong association with TIS. b, Senescence-selective gene set enrichment pattern of 
proliferation- and stem-cell-related gene modules (including haematopoietic stem cell (HSC) and 
long-term HSC (LT-HSC) signatures)
56,58-60
 in control;bcl2 and Suv39h
−
;bcl2 lymphoma cells as 
in Fig. 1a. GSEA based on the Kolmogorov–Smirnov test, with negative NES indicating 
enrichment in untreated lymphomas, and positive NES reflecting enrichment in TIS. n = 12 
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biologically independent control;bcl2 samples and n = 5 Suv39h
−
;bcl2 samples. NES of P < 0.05 
are considered statistically significant and are shown in red. c, Senescence induction by ADR 
treatment in various human cell lines consisting of haematological malignancies, colorectal 
cancers, melanomas, or in primary samples from patients with B-CLL as determined by SA--gal 
staining (mean percentage of positive cells ± s.d., n = 3 independent experiments for cell lines; 
n = 4 individual B-CLL samples). TIS-competent cells are defined by a greater than fourfold 
induction of SA--gal-positive cells (with the exception of B-CLL samples, in which SA--gal-
positive cells were at least threefold induced), and depicted as a blue box symbol in Fig. 1c. d, 
ABC transporter activity in cells as in Fig. 1a, measured by the efflux of a fluorescent substrate 
with and without the ABC transporter inhibitor verapamil. Representative plots of four 
independent lymphomas tested per genotype. e, Enhanced expression of the stem cell marker 
CD34 in the RCK8 cell line or primary human B-cell leukaemia samples exposed to ADR 
treatment in vitro. Mean fluorescence intensity ± s.d. from three independent experiments (RCK8 
cells) and five individual leukaemia cases determined by flow cytometry. Two-tailed, unpaired t-
test with Welch’s correction, *P < 0.05. f, TIS-mediated increase and verapamil-dependent 
blockage of ABC transporter activity in ADR-senescent RCK8 cells and primary human B-cell 
leukaemia samples as in e. One representative out of three independent experiments shown. g, 
SAS occurring in non-malignant senescence scenarios: GSEA of proliferation- or stem-cell-
related gene sets (as in b) in publicly available transcriptome data representing different models 
of replicative senescence: primary human mammary epithelial cells in stasis or agonescence 
(GSE16058, 12 prestasis, 9 stasis and 4 agonescence individual biological samples), high-passage 
BJ human skin fibroblasts (GSE13330, n = 6 pairs of proliferating/senescent cells from 
individual donors) or high-passage primary human mesenchymal stem cells (GSE9593, n = 3 
pairs of proliferating/senescent cells from individual donors). 
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 Extended Data Figure 2 | Genetic, biochemical and functional properties of regulatable 
senescence models. a, Graphic illustration of the model system engineered to stably express a 
regulable senescence-essential gene moiety, such as Suv39h1
− 
proficient and -deficient Eµ-Myc 
transgenic and bcl2-infected lymphoma variants of which only Suv39h1
−
;bcl2;Suv39h1·ER
T2
 
cells regain conditional TIS capability if exposed to 4-OHT. b, Relative transcript levels of the 
indicated stem-cell-related and Wnt target (asterisk) genes by qRT–PCR in 
Suv39h1
−
;bcl2;Suv39h1·ER
T2
 lymphoma cells exposed to the indicated treatments for five days. 
Results represent mean fold induction relative to the untreated condition ± s.d. (n = 3 biologically 
independent samples). c, Global proteome analysis of total Suv39h1
−
;bcl2;Suv39h1·ER
T2
 cell 
lysates after five days of ADR ± 4-OHT treatment, showing mean protein expression changes 
relative to untreated condition (x axis) and their statistical significance (y axis), n = 3 biologically 
independent samples analysed by Wilcoxon test. All identifications with a −log10 transformed P 
value >1 were considered significant. Dots representing ATSC factors are highlighted in orange. 
d, Immunoblot of H3K9me3 expression in Suv39h1
−
;bcl2;Suv39h1·ER
T2
 lymphoma cells treated 
25
as in b (‘Treatment’), and monitored at the indicated passages in 4-OHT/ADR-free medium 
(‘Post-treatment’; p1–3, each passage reflects 7 days in culture). Never senescent, ADR-only- 
and previously senescent ADR+4-OHT-pretreated lymphoma cells are analysed, -tubulin is 
used as a loading control. One out of two independent experiments shown. For gel source data, 
see Supplementary Fig. 1. e, f, Growth curve analysis (e) and SA--gal reactivity time course (f) 
of cells treated as in d. Results represent mean cell numbers or percentages of positive cells, 
respectively ± s.d., from three biologically independent samples. g, Kinetics of the proliferation 
marker EdU and the fluorescent SA--gal marker in Suv39h1−;bcl2;Suv39h1·ERT2 lymphoma 
cells after five days of ADR ± 4-OHT treatment (‘Treatment’), and subsequent passages in 4-
OHT/ADR-free medium (‘Post-treatment’, p1–3, each passage reflecting seven days in culture), 
demonstrating outgrowth of senescent (SA--gal+) cells after terminating the 4-OHT/ADR 
treatment. Mean percentages of EdU
+
/SA--gal+ and EdU+/SA--gal− cells ± s.d., n = 4 
biologically independent samples. Representative photomicrographs from cell popoulations 
marked by red circles are shown in Fig. 2a. h, Competition assays of matched passage 2 
previously senescent (GFP-labelled) and never senescent (DsRed-labelled) lymphomas plated at 
an equal ratio (top) and evaluated by fluorescence microscopy-scored colony formation in vitro 
(bottom left), and by flow cytometric analysis of lymphoma cells isolated from manifest tumours 
after transplantation (bottom right). Numbers reflect the ratio of red- to green-fluorescent 
colonies or cells, respectively. One representative out of four independent experiments shown, 
including colour reversal. 
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 Extended Data Figure 3 | Senescence-released (previously senescent) cancer cells display 
higher tumour-initiating capacity than their never-senescent counterparts. a–d, Growth 
properties of conditionally senescent lymphoma cells analysed as in Fig. 2a, b, but using 
p53·ER
Tam
;bcl2 lymphoma cells with ADR ± 4-OHT treatment (a, b), or 
Suv39h1
−
;bcl2;Suv39h1·ER
T2
 lymphoma cells exposed to a single dose of -irradiation (8 Gy) 
instead of ADR, followed by five days of 4-OHT treatment and subsequent passaging in 4-OHT-
free medium (c, d). Results presented as mean positive cells or mean colony numbers ± s.d.; 
n = 4 (a, c, d) or n = 3 (b) biologically independent samples. Representative photomicrographs 
from one out of three independent experiments (a, c). Two-tailed, unpaired t-test with Welch’s 
correction, comparing ADR- and 4-OHT+ADR pretreated lymphomas at p6, or 8 Gy- and 4-
OHT+8 Gy at p5. *P < 0.05 (b, d). It is noteworthy that the superior growth and clonogenicity of 
post-senescent cells can be explained neither by rare cells that may simply have bypassed 
senescence, because the matching never senescent (i.e. senescence bypasser) group presented 
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with inferior clonogenicity, nor by an enhanced death rate of non-stem cells in the Suv39h1-
proficient aliquot, because no significant differences in viability were observed between never 
senescent and previously senescent groups throughout these experiments. Viability determined by 
flow cytometry as the percentage of AnnexinV/PI double-negative cells was typically greater 
than 80% and comparable between never senescent and previously senescent cells (not shown; 
the same applies for Fig. 2a and Fig. 4a). Growth-promoting mutations are also unlikely, as 
senescent cells stopped replicating their DNA. e, f, Colony formation assay of untreated versus 
five-day-ADR-senescent human RCK8 lymphoma cells (e) or LT174T colon carcinoma cells (f) 
that were exposed to a shp53-lentivirus or mock infection on day five of ADR treatment, with 
p53 knock-down enabling outgrowth out of fully established senescence. As observed for mouse 
lymphoma cells, post-senescent RCK8 and LT174T cells, after just three passages, outperformed 
the clonogenic potential of tumor cells that were equally exposed to shRNA against p53 but never 
experienced senescence. Results represent mean colony numbers at indicated passages (each 
reflecting seven days in ADR-free methylcellulose medium) ± s.d., n = 3 independent 
experiments. Two-tailed, unpaired t-test with Welch’s correction, comparing untreated shp53 
versus ADR + shp53 at p5 (e) or p4 (f). *P < 0.05. g, TIS re-inducibility in 
Suv39h1
−
;bcl2;Suv39h1·ER
T2
 previously senescent cells (at passage 2, compare with Fig. 2a) re-
exposed to 4-OHT and ADR for five days, as detected by SA--gal staining (up) and BrdU/PI 
incorporation (down). Results represent mean percentages of positive cells ± s.d. (n = 4 
independent lymphomas). 
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 Extended Data Figure 4 | The senescence-associated secretory phenotype (SASP) is 
dispensable for senescence-associated stemness (SAS) induction. a, Expression of a panel of 
SASP transcripts
40,57
 by qRT–PCR in Suv39h1-regulable lymphoma cells after five days of 
ADR ± 4-OHT exposure, and after two passages in 4-OHT/ADR-free medium (that is, in never 
senescent and previously senescent cells), showing SASP upregulation in TIS and its 
downregulation back to baseline levels in senescence-released previously senescent cells. Results 
represent mean fold induction relative to untreated lymphomas ± s.d. (n = 3 biologically 
independent samples). b, Blunting SASP production (top) by NF-B super-repressor IBN 
(NF-B-SR)-mediated genetic inhibition of NF-B as the major SASP driver in TIS cells 
(without compromising their ability to enter TIS)
9,40
 did not prevent acquisition of stemness 
markers (bottom) by qRT–PCR. Results represent mean fold induction relative to mock-
transduced untreated cells ± s.d. (n = 4 biologically independent samples). c, Co-expression of 
the stem-cell marker Sca1 and the TIS marker H3K9me3 by flow cytometry in NF-B-SR-
expressing control;bcl2 cells exposed to ADR for five days, indicating uncompromised SAS 
induction. Percentages indicate mean Sca1/H3K9me3 double-positive cells ± s.d. (n = 4 
biologically independent samples). d, ABC transporter activity by flow cytometry in 
control;bcl2;NF-B-SR cells as in c, again demonstrating strong induction of stem cell-
reminiscent ABC transporter activity in TIS cells (compare with Extended Data Fig. 1d) 
irrespective of their blunted SASP response. Representative plots out of four independent 
lymphomas shown. 
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 Extended Data Figure 5 | Wnt signalling is upregulated in senescence. a, GSEA of gene sets 
probing stem cell-relevant signalling pathways in ADR-senescent control;bcl2 or TIS-
incompetent Suv39h1
−
;bcl2 cells (as in Fig. 1a). Positive NES indicate enrichment in TIS 
lymphomas. NES of P < 0.05 are considered statistically significant and are presented in red. 
n = 12 pairs of independent lymphomas b, GSEA enrichment plots of selected gene sets 
presented in a; GO term ‘Canonical Wnt receptor signaling’ (top) or subset of proliferation-
relevant Wnt target genes (bottom), showing significant enrichment in ADR-senescent 
control;bcl2 but not in TIS-incompetent Suv39h1
−
;bcl2 cells. c, Immunoblot analysis of Serine 
37- and Threonine 41-dephosphorylated (that is, stabilized and nucleus translocation-capable 
‘Active -catenin’) and total -catenin in three independent pairs of control;bcl2 and Suv39h1−; 
bcl2 lymphoma cells, exposed to ADR for 5 days (+) or left untreated (−). -Tubulin is used as a 
loading control. One out of two independent experiments shown. For gel source data, see 
Supplementary Fig. 1. d, Wnt activity measured by the TOPflash TCF reporter system (with 
FOPflash as negative control) in human cell lines in correlation with their senescence inducibility 
by ADR, as indicated by blue box symbols for senescence-competent cell lines (referring to 
Extended Data Fig. 1c). Results reflect mean relative light units fold change (between untreated 
and ADR-treated samples) of three independent experiments ± s.d. 
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 Extended Data Figure 6 | Cell-intrinsic activation of Wnt signalling cascade in TIS. a, b, 
Expression of indicated stem-cell-related transcripts by qRT–PCR (a) and colony formation (b) 
in control;bcl2 lymphomas infected with a constitutively active -catenin mutant (N-catenin) or 
a mock retrovirus. Data represent mean expression fold change normalized to mock-infected cells 
and mean colony numbers, respectively ± s.d. (n = 3 biologically independent samples). Two-
tailed, unpaired t-test with Welch’s correction. *P < 0.05. c, Immunoblot analysis of Serine 9-
phosphorylated (i.e. inactivated) or total GSK3, active or total -catenin (as in Extended Data 
Fig. 5c), Threonine 202- and Tyrosine 204-phosphorylated or total Erk1/2, and Serine 473-
phosphorylated or total Akt in control;bcl2 lymphoma cells treated with ADR for five days, 
together with pharmacological inhibitors targeting MAPK and PI3K kinase pathways. -Tubulin 
was used as a loading control. One out of two independent experiments shown. For gel source 
data, see Supplementary Figure 1. d, Expression of the indicated stem-cell-related transcripts by 
qRT–PCR in never senescent and previously senescent Suv39h1−;bcl2;Suv39h1·ERT2 cells 
(passage 2) exposed to Wnt signaling agonists (Wnt3a, Rspo2, or GSK3 inhibitor) for two days. 
Color scale represents mean fold change normalized to never senescent cells not exposed to Wnt 
agonists ± s.d. (n = 3 individual lymphomas). e, Colony formation of never senescent and 
previously senescent cells (as in d), after seven days in methylcellulose medium supplemented 
with the indicated Wnt agonists (mean colony numbers ± s.d., n = 3 individual lymphomas). 
Two-tailed, unpaired t-test with Welch’s correction. *P < 0.05. 
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 Extended Data Figure 7 | Wnt signalling is dispensable for senescence induction, but 
required for senescence-associated stemness. a, Senescence induction by ADR in control;bcl2 
lymphoma cells with and without parallel application of the indicated pharmacological or genetic 
Wnt inhibitors (ICG-001, salinomycin or -catenin knock-down by shRNA (sh-catenin)). 
Results reflect mean percentages of SA--gal-positive cells ± s.d. (n = 4 independent 
lymphomas). b, Expression of stemness-related transcripts by qRT–PCR in ADR-treated 
control;bcl2 lymphoma cells exposed to -catenin knock-down by shRNA retroviral infection 
(sh-catenin). The colour scale represents mean fold induction normalized to ADR-untreated (ut) 
and vector-infected controls ± s.d. (n = 3 biologically independent samples). c, Relative viability 
of Suv39h1
−
;bcl2;Suv39h1·ER
T2
 cells exposed to the indicated Wnt inhibitors either 
simultaneously with ADR ± 4-OHT treatment (for the last 48 h of treatment), or at passage 2 
after terminating ADR ± 4-OHT (never senescent and previously senescent; treated over 48 h 
with inhibitors). Results show relative viability normalized to sample with no Wnt inhibitor 
treatment ± s.d. (n = 3 biologically independent samples). d, Colony formation of human LT174T 
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colon carcinoma cells exposed to mock or shp53-lentivirus upon ADR-induced senescence, and 
further propagated in ADR-free medium (corresponding to passage 3 in Extended Data Fig. 3f). 
Results show mean colony counts after seven-day exposure to indicated Wnt inhibitors ± s.d. 
(n = 3 independent experiments per group). Two-tailed, unpaired t-test with Welch’s correction, 
*P < 0.05. e, Individual survival times of the six matched never senescent and previously 
senescent lymphoma pairs (shown collectively in Fig. 3d). f, Individual survival times of mice 
bearing never senescent (left) and previously senescent lymphomas (right) after exposure to Wnt 
signaling inhibition by -catenin knock-down (sh-catenin) or left uninhibited (ut). The line plots 
represent the same matched never senescent and previously senescent lymphomas as in e. 
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 Extended Data Figure 8 | The previously senescent cell population maintains a stable 
fraction of Wnt-active stem cells over time. a, Detection of a slowly dividing subpopulation in 
previously senescent but not in never senescent lymphoma cells (arrow) by the CFSE membrane 
dye 1, 4 or 8 days after stopping the ADR ± 4-OHT treatment. Experiment performed in 
triplicates. b, CFSE
high
 previously senescent cells exhibited more profound nuclear -catenin 
expression, indicating acquired stemness (passage 3 after 4-OHT/ADR removal; compare with c). 
One out of three independent experiments, each performed in triplicate. c, Co-staining with -
catenin and CFSE as in b in Suv39h1
−
;bcl2;Suv39h1·ER
T2
 cells, untreated or exposed to 
ADR ± 4-OHT for five days (‘Treatment’) and subsequently passaged in 4-OHT/ADR-free 
medium (p1–2; each passage reflects seven days in culture). The slowly cycling (CFSEhigh) 
population was positive for -catenin and persisted over time, although their relative percentage 
drops owing to outgrowth of their (CFSE
low
) progeny. Numbers reflect mean percentages from 
three independent lymphomas ± s.d. d, e, Higher expression of ATSC- or Wnt-related (asterisk) 
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transcripts by qRT–PCR (d) and higher clonogenic capacity, which can be neutralized by 
indicated pharmacological or genetic Wnt inhibitors (e) in flow-sorted, -catenin high versus -
catenin low previously senescent cells (passage 3 after 4-OHT/ADR removal). Mean expression 
levels normalized to untreated cells and mean colony numbers respectively ± s.d., n = 4 
biologically independent samples. Two-tailed, unpaired t-test with Welch’s correction, *P < 0.05. 
f, Immunoblot analysis of -catenin and H3K9me3 levels in human RCK8 lymphoma cells 
exposed to ADR for 5 days to induce senescence (‘Treatment’), then stably transduced with an 
shp53- or mock lentivirus, and further propagated in ADR-free medium (‘Post-treatment’, p1–5, 
each reflecting seven days in culture). The senescence-associated high levels of active and total 
-catenin achieve a low but stable level at later passages. It is noteworthy that stably senescent 
ADR-pretreated, mock-infected cells were only blotted in p1. One representative out of three 
independent experiments shown, with -tubulin as a loading control. For gel source data, see 
Supplementary Fig. 1. g, Co-expression of -catenin and the stem cell marker CD34 detected by 
flow cytometry in ADR-pretreated, shp53-infected RCK8 cells as in f, demonstrating a small but 
stable steady-state fraction of double-positive cells at later passages, explaining the lastingly 
enhanced colony-forming potential of previously senescent versus never senescent cells. 
Representative flow cytometry plots from three independent experiments (top) and mean 
percentages of double-positive cells ± s.d. (bottom) at the indicated passages (n = 3 independent 
experiments). Two-tailed, unpaired t-test with Welch’s correction. *P < 0.05. 
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Extended Data Figure 9 | Spontaneous escape out of senescence detected in cancer cells 
without genetic manipulations of senescence-relevant genes. Flow cytometric analysis of the 
proliferation marker EdU and a fluorescent SA--gal marker in control;bcl2 cells treated with 
ADR or left untreated (top), and further cultivated in ADR-free medium (bottom). Co-expression 
of EdU in a small population of still SA--gal-positive cells demonstrates the ability of some 
ADR-senescent cells to escape the senescence arrest. Numbers represent mean percentages ± s.d. 
from four independent lymphomas. Photomicrographs depict representative cells from 
populations marked with red circles (n = 4 independent experiments). 
36
 Extended Data Figure 10 | Senescence-associated de novo generation of leukaemia stem cells 
upon depletion of the stem cell-containing fraction in mouse and human leukaemia samples. 
a, Flow cytometry plots of mouse Kras
G12D
;DOX-on-shp53-GFP-induced T-cell acute 
lymphoblastic leukaemias (total splenocytes after short-term culture and retroviral bcl2 
infection), stained with a panel of mouse lineage antibodies before and after flow-based sorting of 
the lin
+
/GFP
+
 population. The lin
−
/GFP
+
 population (including Kit
+
/Sca1
+
 leukaemia stem cells) 
was used as a positive control. Shown are representative plots (n = 3). b, Colony formation of 
mouse lin
+
/GFP
+
 leukaemia cells as in a, pretreated with ADR ± doxycycline (DOX) for 
five days and subsequently seeded in ADR-free/DOX-supplemented medium, thus producing 
never senescent and previously senescent cells, respectively. Results represent mean colony 
counts at passage 2 (each passage reflecting 10 days in culture) ± s.d. (n = 3 biologically 
independent samples). Two-tailed, unpaired t-test with Welch’s correction. *P < 0.05. c, Nuclear 
-catenin expression by immunofluorescence (in red) in equally five-day-ADR-exposed 
senescent versus non-senescent settings (i.e., DOX
−
 versus DOX
+
). DAPI was used as a nuclear 
counterstain (in blue). Numbers represent mean percentages of -catenin-positive cells ± s.d. (n 
= 3 biologically independent samples). d, Colony formation of never senescent and previously 
senescent leukaemia cells pretreated as in b (passage 3) with the addition of the indicated 
pharmacological Wnt inhibitors (mean colony numbers ± s.d., n = 3 biologically independent 
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samples per group). *P < 0.05, two-tailed, paired t-test. e, Senescence induction by SA--gal 
staining in mouse Nras
G12D
;MLL-AF9;DOX-on-shp53;bcl2 bulk AML cells (lin
−
/Kit
+
/Sca1
+
-
depleted) after five days of the ADR ± DOX treatment. Numbers reflect mean percentages of SA-
-gal-positive cells ± s.d (experiment performed in triplicate). Notably, viability determined as 
the percentage of AnnexinV/PI double-negative cells was typically greater than 80% and 
comparable between treatment groups. f, Stemness-related transcripts by qRT–PCR in 
conditionally senescent mouse AML cells as in e. Graphs represent mean fold induction ± s.d. (n 
= 3 independent experiments). g, Colony formation of mouse bulk leukaemia cells pretreated as 
in e, further propagated in ADR-free DOX-containing medium for 14 days, and plated in 
methylcellulose medium supplemented with the Wnt inhibitors ICG-001 or salinomycin. 
Colonies were counted after seven days. Previously senescent AML cells, emerging via DOX-
mediated p53 knockdown, presented with the highest, Wnt-dependent clonogenicity, which could 
be attenuated by pharmacological Wnt inhibition. Results represent mean colonies ± s.d. (n = 3 
independent experiments). Two-tailed, unpaired t-test with Welch’s correction. *P < 0.05. h, 
Colony formation of the CD34
+
 cell-depleted human AML cell line Molm13 (with constitutive 
retroviral Bcl2-expression) exposed to senescence-inducing ADR treatment for five days 
(‘Treatment’) and subsequently transduced with the lentiviral shp53 or mock construct (p53-
knock-down enabling outgrowth from fully established senescence). Results reflect mean colony 
numbers ± s.d. (n = 3 independent experiments). Two-tailed, unpaired t-test with Welch’s 
correction. *P < 0.05. i, Flow cytometric detection of the CD33 myeloid differentiation marker 
and CD34 stem cell marker surface expression in samples from patients with AML obtained at 
diagnosis, before any cell cultivation and after six days of cultivation in vitro. Representative 
plots are shown (n = 5 individual patient samples). j, Expression of stemness-related transcripts 
in five-day-ADR-senescent versus untreated, ex vivo CD34
+
-depleted primary human AML cells 
as in i (qRT–PCR; average fold induction ± s.d., n = 5 individual patient samples, left). 
Photomicrographs (right) confirm ADR-inducible senescence by SA--gal staining (mean 
percentages of SA--gal positive cells ± s.d., representative photomicrographs from five 
independent samples). k, Regained CD34 surface expression upon ADR-induced senescence in 
CD34
+
-depleted primary human AML cells as presented in j. Numbers reflect mean fluorescence 
intensity detected by flow cytometry ± s.d. (n = 5 individual patient samples). Two-tailed, paired 
t-test, *P < 0.05. l, ABC transporter activity in ADR-senescent versus untreated cells as in k. 
Representative plots are shown (n = 5 individual samples). 
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